ArticleMolecular therapy. Nucleic acids2025

MiR-34 at the crossroads of SMA pathogenesis and therapy: Emerging biomarker and therapeutic target.

Jun-An ChenPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.